ALK is altered in 5.44% of non-small cell lung carcinoma patients with ALK Amplification present in 0.02% of all non-small cell lung carcinoma patients [4].

ALK Amplification is an inclusion criterion in 20 clinical trials for non-small cell lung carcinoma, of which 13 are open and 7 are closed. Of the trials that contain ALK Amplification and non-small cell lung carcinoma as inclusion criteria, 4 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), 8 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), 4 are phase 3 (4 open), and 1 is phase 4 (1 open) [5].

ALK is altered in 3.57% of malignant solid tumor patients with ALK Amplification present in 0.1% of all malignant solid tumor patients [4].

ALK Amplification is an inclusion criterion in 12 clinical trials for malignant solid tumor, of which 5 are open and 7 are closed. Of the trials that contain ALK Amplification and malignant solid tumor as inclusion criteria, 4 are phase 1 (0 open), 4 are phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].

ALK is altered in 2.64% of diffuse large B-cell lymphoma patients [4].

ALK Amplification is an inclusion criterion in 9 clinical trials for diffuse large B-cell lymphoma, of which 9 are open and 0 are closed. Of the trials that contain ALK Amplification and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 2 are phase 3 (2 open) [5].

ALK Amplification is an inclusion criterion in 7 clinical trials for ALK-positive large B-cell lymphoma, of which 7 are open and 0 are closed. Of the trials that contain ALK Amplification and ALK-positive large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

ALK is altered in 2.91% of diffuse large B-cell lymphoma, not otherwise specified patients [4].

ALK Amplification is an inclusion criterion in 6 clinical trials for diffuse large B-cell lymphoma, not otherwise specified, of which 6 are open and 0 are closed. Of the trials that contain ALK Amplification and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (2 open), and 2 are phase 3 (2 open) [5].

ALK Amplification is an inclusion criterion in 6 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 6 are open and 0 are closed. Of the trials that contain ALK Amplification and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

ALK Amplification is an inclusion criterion in 6 clinical trials for T-cell/histiocyte-rich large B-cell lymphoma, of which 6 are open and 0 are closed. Of the trials that contain ALK Amplification and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (2 open), and 2 are phase 3 (2 open) [5].

ALK Amplification is an inclusion criterion in 6 clinical trials for transformed non-hodgkin lymphoma, of which 6 are open and 0 are closed. Of the trials that contain ALK Amplification and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

ALK is altered in 3.42% of cancer patients with ALK Amplification present in 0.1% of all cancer patients [4].

ALK Amplification is an inclusion criterion in 5 clinical trials for cancer, of which 2 are open and 3 are closed. Of the trials that contain ALK Amplification and cancer as inclusion criteria, 3 are phase 1 (2 open) and 2 are phase 2 (0 open) [5].

ALK is altered in 22.86% of anaplastic large cell lymphoma patients [4].

ALK Amplification is an inclusion criterion in 5 clinical trials for anaplastic large cell lymphoma, of which 4 are open and 1 is closed. Of the trials that contain ALK Amplification and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open) [5].

ALK Amplification is an inclusion criterion in 5 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 5 are open and 0 are closed. Of the trials that contain ALK Amplification and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

ALK Amplification is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma associated with chronic inflammation, of which 4 are open and 0 are closed. Of the trials that contain ALK Amplification and diffuse large B-cell lymphoma associated with chronic inflammation as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

ALK Amplification is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ALK Amplification and double-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

ALK Amplification is an inclusion criterion in 4 clinical trials for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 4 are open and 0 are closed. Of the trials that contain ALK Amplification and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 4 clinical trials for grade 3b follicular lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ALK Amplification and grade 3b follicular lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

ALK Amplification is an inclusion criterion in 4 clinical trials for intravascular large B-cell lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ALK Amplification and intravascular large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

ALK Amplification is an inclusion criterion in 4 clinical trials for primary cutaneous diffuse large B-cell lymphoma, leg type, of which 4 are open and 0 are closed. Of the trials that contain ALK Amplification and primary cutaneous diffuse large B-cell lymphoma, leg type as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

ALK is altered in 13.48% of neuroblastoma patients with ALK Amplification present in 1.17% of all neuroblastoma patients [4].

ALK Amplification is an inclusion criterion in 3 clinical trials for neuroblastoma, of which 2 are open and 1 is closed. Of the trials that contain ALK Amplification and neuroblastoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [5].

ALK Amplification is an inclusion criterion in 3 clinical trials for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 3 are open and 0 are closed. Of the trials that contain ALK Amplification and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (1 open) [5].

ALK Amplification is an inclusion criterion in 3 clinical trials for mediastinal large B-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain ALK Amplification and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

ALK Amplification is an inclusion criterion in 3 clinical trials for triple-hit lymphoma, of which 3 are open and 0 are closed. Of the trials that contain ALK Amplification and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

ALK is altered in 7.69% of melanoma patients with ALK Amplification present in 0.05% of all melanoma patients [4].

ALK Amplification is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain ALK Amplification and melanoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ALK is altered in 1.71% of B-cell non-hodgkin lymphoma patients [4].

ALK Amplification is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK Amplification and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ALK is altered in 6.25% of Burkitt lymphoma patients [4].

ALK Amplification is an inclusion criterion in 2 clinical trials for Burkitt lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK Amplification and Burkitt lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ALK is altered in 1.23% of follicular lymphoma patients [4].

ALK Amplification is an inclusion criterion in 2 clinical trials for follicular lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK Amplification and follicular lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 2 clinical trials for germinal center B-cell-like diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK Amplification and germinal center B-cell-like diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [5].

ALK Amplification is an inclusion criterion in 2 clinical trials for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 2 are open and 0 are closed. Of the trials that contain ALK Amplification and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [5].

ALK is altered in 2.25% of lymphoma patients [4].

ALK Amplification is an inclusion criterion in 2 clinical trials for lymphoma, of which 0 are open and 2 are closed. Of the trials that contain ALK Amplification and lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [5].

ALK Amplification is an inclusion criterion in 2 clinical trials for lymphomatoid granulomatosis, of which 2 are open and 0 are closed. Of the trials that contain ALK Amplification and lymphomatoid granulomatosis as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ALK is altered in 0.56% of mantle cell lymphoma patients [4].

ALK Amplification is an inclusion criterion in 2 clinical trials for mantle cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK Amplification and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ALK is altered in 1.92% of pancreatic carcinoma patients [4].

ALK Amplification is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ALK Amplification and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 2 clinical trials for plasmablastic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK Amplification and plasmablastic lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ALK Amplification is an inclusion criterion in 2 clinical trials for primary mediastinal B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK Amplification and primary mediastinal B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) [5].

ALK is altered in 2.92% of thyroid gland undifferentiated (anaplastic) carcinoma patients with ALK Amplification present in 0.93% of all thyroid gland undifferentiated (anaplastic) carcinoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK Amplification and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

ALK is altered in 2.97% of glioblastoma patients with ALK Amplification present in 0.21% of all glioblastoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ALK Amplification and glioblastoma as inclusion criteria, 1 is early phase 1 (0 open) [5].

ALK is altered in 2.51% of central nervous system neoplasm patients with ALK Amplification present in 0.09% of all central nervous system neoplasm patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ALK Amplification and central nervous system neoplasm as inclusion criteria, 1 is early phase 1 (0 open) [5].

ALK is altered in 4.52% of bladder carcinoma patients with ALK Amplification present in 0.07% of all bladder carcinoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK is altered in 5.47% of lung carcinoma patients with ALK Amplification present in 0.02% of all lung carcinoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK is altered in 3.16% of adenocarcinoma of the gastroesophageal junction patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 1 is closed. Of the trial that contains ALK Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (0 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, ALK-negative, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and anaplastic large cell lymphoma, ALK-negative as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK is altered in 75.0% of anaplastic large cell lymphoma, ALK-positive patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, ALK-positive, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and anaplastic large cell lymphoma, ALK-positive as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for atypical Burkitt/Burkitt-like lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and atypical Burkitt/Burkitt-like lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK is altered in 1.35% of biliary tract carcinoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and central nervous system lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK is altered in 1.51% of cholangiocarcinoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK Amplification and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

ALK is altered in 4.08% of colorectal carcinoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK Amplification and colorectal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma activated B-cell type, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and diffuse large B-cell lymphoma activated B-cell type as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for EBV-positive mucocutaneous ulcer, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and EBV-positive mucocutaneous ulcer as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for enteropathy-associated T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and enteropathy-associated T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK is altered in 3.34% of esophageal carcinoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK Amplification and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue as inclusion criteria, 1 is phase 1 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for follicular T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and follicular T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK is altered in 2.38% of gastric carcinoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK Amplification and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

ALK is altered in 2.54% of hepatocellular carcinoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK Amplification and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for hepatosplenic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and hepatosplenic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and indolent T-cell lymphoproliferative disorder of the gastrointestinal tract as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for large B-cell lymphoma with IRF4 rearrangement, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 1 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK is altered in 2.08% of malignant salivary gland neoplasm patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK is altered in 1.71% of mature B-cell non-hodgkin lymphoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK is altered in 5.28% of mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for monomorphic epitheliotropic intestinal T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and monomorphic epitheliotropic intestinal T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK is altered in 6.45% of mycosis fungoides patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and mycosis fungoides as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for nasal type extranodal NK/T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and nasal type extranodal NK/T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for nodal marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and nodal marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for nodal peripheral T-cell lymphoma with TFH phenotype, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and nodal peripheral T-cell lymphoma with TFH phenotype as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK is altered in 2.47% of non-hodgkin lymphoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK is altered in 1.96% of pancreatic adenocarcinoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK Amplification and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ALK is altered in 2.65% of peripheral T-cell lymphoma, not otherwise specified patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and primary central nervous system lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for primary effusion lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and primary effusion lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and Richter syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for sezary syndrome, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and sezary syndrome as inclusion criteria, 1 is phase 2 (1 open) [5].

ALK is altered in 3.95% of small intestinal carcinoma patients [4].

ALK Amplification is an inclusion criterion in 1 clinical trial for small intestinal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK Amplification and small intestinal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for subcutaneous panniculitis-like T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and subcutaneous panniculitis-like T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ALK Amplification is an inclusion criterion in 1 clinical trial for systemic EBV-positive T-cell lymphoma of childhood, of which 1 is open and 0 are closed. Of the trial that contains ALK Amplification and systemic EBV-positive T-cell lymphoma of childhood as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].